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Abstract 
 Adjuvant chemotherapy  use on early stages non-small cell lung cancer patients 
remains the debatable issue. For individualization purpose of adjuvant chemotherapy  
administration it is possible to use molecular prognostic/predictive markers. The goal of our 
study was to investigate the adjuvant chemotherapy  effectiveness on early stage NSCLC 
patients depending on the various molecular markers expression in primary tumor. Included 
in research are 254 patients with І–ІІ stage non-small cell lung cancer (NSCLC) that received 
institutional treatment in the department of thoracic surgery of Zaporizhyzhya Regional 
Clinical Oncologic Dispensary starting from June of 2008 up to December of 2012. For 
adjuvant chemotherapy  administration individualization purpose the following molecular 
markers were used: Ki-67, CD31/CD34, Pan-Cytokeratin, Her-2/neu, p53, E-cadherin, EGFR. 
Low Кі-67, CD31/CD34, р53 expression level is a marker of adjuvant chemotherapy  
negative influence on early stage NSCLC patients survival rate. Alternatively, at high 
expression level of the said markers the adjuvant chemotherapy  administration significantly 
improves examined patients survival rate. Pan-Cytokeratin indicates the presence of 
micrometastases in the lung root lymph nodes, and those are such patients, whose survival 
rate is improved by adjuvant chemotherapy  conduction. Her-2/neu is the marker of tumor 
chemoresistance, more specifically, for patients with high expression level of such marker 
conducting of adjuvant chemotherapy is not appropriate, because this type of treatment does 
not improve survival at indicated marker characteristics. At the same time, low level of Her-
2/neu expression is a marker of chemosensivity and adjuvant chemotherapy  conduction on 
such patients improves their survival rate. Significant predictive connection of E-cadherin 
EGFR expression level, high Her-2/neu expression and the absence of micrometastases is not 
established. 
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Introduction:  
Surgery remains the basic method of treatment for patients with early (I-II) stages of 
non-small cell lung cancer (NSCLC). However, for 50-60% of patients the disease 
progression occurs after surgical interference. In order to improve outcomes of patients with 
early stages of NSCLC the use of adjuvant chemotherapy on the basis of platinum-based 
drugs is possible. Adjuvant chemotherapy effectiveness for this category of patients is still 
debated. A number of studies found no improvement in survival rate in patients after 
conducting of adjuvant chemotherapy [5,6,8]. According to other authors’ data adjuvant 
chemotherapy is effective for patients with II and IIIA stages of NSCLC [1,2,7,9]. 
Perhaps, the difference of the received data is due to the heterogeneity of patients 
involved in the research. Today it is known that NSCLC patients form the heterogeneous 
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group, even within the same stage, which is associated with tumor molecular characteristics 
[3,4]. Molecular markers may be used in order to separate subgroups. 
Materials and Methods: 254 patients with І–ІІ stage non-small cell lung cancer 
(NSCLC) that received institutional treatment in the department of thoracic surgery of 
Zaporizhyzhya Regional Clinical Oncologic Dispensary are included in research. Patients’ 
average age amounts to 60,7 years (95% CI 59,7-61,7). All patients underwent surgical 
treatment in the amount of lobectomy or pneumonectomy. Adjuvant chemotherapy  was 
conducted for 52 patients with I stage of NSCLC and 49 patients with II stage of the disease. 
Adjuvant chemotherapy  conduction for patients with I stage of NSCLC is not the care 
standard, in connection with which after explaining of all the possible positive and negative 
adjuvant chemotherapy  effects, 119 patients refused additional therapy offer. Part of the 
patients with stage II (n=34) did not receive adjuvant chemotherapy due to comorbidity, or 
rejection of this type of treatment. Adjuvant chemotherapy  involved 2-3 courses of platinum-
based chemotherapy (80mg/m2 of cisplatin for 1 day, 120 mg/m2 of etoposide from the 1st to 
the 3rd day, with 21-day interval between the courses). Chemotherapy treatment was initiated 
within 21 days after surgery. 
For adjuvant chemotherapy  administration individualization purpose the following 
molecular markers were used: Ki-67, CD31/CD34, Pan-Cytokeratin, Her-2/neu, p53, E-
cadherin, EGFR. 
Х2 criterion and Pearson's chi-squared test were used for patients with adjuvant 
chemotherapy  and without additional treatment in order to evaluate the connection between 
various clinical and morphological features. The survival rate was estimated using the 
Kaplan-Mayer function. Survival rate difference of individual groups was examined using 
log-rank criterion. The significance level was defined as р<0.05. Statistica 6.0. Software 
package was used for material statistical processing.  
Results of research: One of the most important tumor properties is its proliferative 
activity. The adjuvant chemotherapy  effectiveness was analyzed for patients with low and 
high proliferative activity. For patients with low proliferative activity median survival after 
conducting of adjuvant chemotherapy  amounted to 25 ± 3,7 months, while for patients for 
whom the additional treatment was not conducted the survival rate was significantly higher 
(р<0,001) - median survival was not reached (Fig. 1.). In other words for patients with low 
proliferation level the conducting of adjuvant chemotherapy  significantly worsens their 
survival rate. 
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Fig. 1. Patients’ survival rate at early NSCLC stage with low proliferative activity level depending on adjuvant 
chemotherapy  administration 
 
However, for patients with high proliferation in primary tumor, who had received 
adjuvant chemotherapy , survival rate considerably increased (р<0,001, Fig. 2.). 
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Fig. 2. Patients’ survival rate at early NSCLC stage with high proliferative activity level depending on adjuvant 
chemotherapy  administration (institution) 
 
Thus, for patients with high proliferation index, which had received adjuvant 
chemotherapy, the median survival was not achieved. The 75th percentile of survival equals 
to 38 ± 11,4 months. The survival rate of patients that had not received additional 
chemotherapy treatment was almost two times less. In this case 75th percentile of survival 
rate amounted to 11,0 ± 1,8 months. Therefore, conducting of adjuvant chemotherapy  is only 
necessary for patients with high malignant neoplasms proliferative activity. 
Another molecular factor that was analyzed was the tumor microvessels density (MD), 
which was analyzed with the help of CD31/CD34 expression. For patients with low tumor 
MD that had received adjuvant chemotherapy  in the postoperative period, median survival 
amounted to 42.0 months, whereas for patients with a similar molecular characteristics of the 
tumor that had not received adjuvant chemotherapy  this indicator was not achieved. Survival 
rate in two groups was different (р=0,005, Fig. 3). 
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Fig. 3. Patients’ survival rate at early NSCLC stage with low microvessels density level depending on adjuvant 
chemotherapy  administration 
 
For patients with high tumor microvessels density level the conducting of adjuvant 
chemotherapy  conversely improved distant survival rate (р=0,003, Fig. 4.). Thus, the median 
survival of patients with high primary tumor MD after further postoperative chemotherapy 
was not achieved, while the median survival of patients without adjuvant chemotherapy  was 
30.0 months. 
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Fig. 4. Patients’ survival rate at early NSCLC stage with high microvessels density level depending on adjuvant 
chemotherapy  administration. 
 
Thus, there is a need of adjuvant chemotherapy  conducting only in cases with high 
primary tumor MD and it is of no use when MD is low.  
Another factor except for the proliferative activity and tumor MD that was analyzed is 
the existence of micrometastases in the lung root lymph nodes, which was assessed with the 
help of Pan-Cytokeratin expression. In the absence of micrometastases the survival rate of 
patients did not change after adjuvant chemotherapy appointment (р=0,884). Thus, the 
median survival was not achieved within the group of patients without micrometastases and 
without adjuvant chemotherapy  conducting and for patients without micrometastases with 
conducting of adjuvant chemotherapy. This indicates adjuvant chemotherapy  efficacy lack 
for patients without micrometastases. Additional chemotherapy effectiveness assessment for 
patients with micrometastases on the contrary showed a significant difference in survival rate 
of patients with and without adjuvant chemotherapy  conducting (р=0,005, Fig. 5). Thus, the 
median survival rate of patients with micrometastases in the lung root lymph nodes after 
conducting of adjuvant chemotherapy  was not achieved, while the median survival of 
patients without additional treatment was 13,0±6,3 months.    
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Fig. 5. Patients’ survival rate at early NSCLC stage with micrometastases in the lymph nodes of root of the lung 
depending on adjuvant chemotherapy  administration. 
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In recent years, increasing attention was paid to the status of the epidermal growth 
factor receptor in primary lung tumors. In our research, we have examined the EGFR and 
Her-2/neu expression, and also analyzed the adjuvant chemotherapy  effectiveness depending 
on indicated markers expression level. 
Patients with low EGFR expression level: median survival is not achieved by patients 
without further treatment in the postoperative period and as well as by patients with 
conducting of adjuvant chemotherapy. The difference in the survival of two groups was not 
statistically significant (р=0,877). Similar results were obtained for patients with high EGFR 
expression level. The median survival rate of patients with adjuvant chemotherapy  amounted 
to 25.0 months, and patients without adjuvant chemotherapy  - 30.0 months. There is no 
difference in survival rate (р=0,560). Therefore, the expression of EGFR is not a predictive 
factor for adjuvant chemotherapy  efficiency for patients with early-stage NSCLC. 
The studied patients in terms of Her-2/neu predictive role, were also divided into 
groups of patients with low and high levels of marker expression. 75th percentile survival rate 
was not achieved for patients with low Her-2/neu expression after conducting of additional 
treatment. At the same time, patients with low expression and no adjuvant chemotherapy  had 
a significantly lower survival rate - 75th percentile survival amounted to 41 months (p = 
0.019, Fig. 6). 
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Fig. 6. Patients’ survival rate at early NSCLC stage with low Her-2/neu expression level depending on adjuvant 
chemotherapy  administration 
 
For patients with high Her-2/neu expression level adjuvant chemotherapy  conduction 
impact was not observed (р=0,880). The median survival of patients with adjuvant 
chemotherapy  amounted to 18.0 months, and in the absence of additional postoperative 
chemotherapy - 21.0 months. 
Thus, high level of Her-2/neu indicates tumor chemoresistance. 
The following researched the molecular marker is р53 apoptosis marker. Apoptosis is 
one of tissue important properties, including the tumor tissue. In order to conduct the research 
of adjuvant chemotherapy  predictive value, all patients included in the research were divided 
into groups of patients with high and low levels of p53 expression, and then the survival rate 
was determined in each group, depending on adjuvant chemotherapy  conducting. 
As shown in Figure 7 significant difference in the survival rate of patients with low 
p53 expression was marked, moreover, patients who had received chemotherapy had 
significantly worse survival rate (median survival - 26.0 months) compared to the patients 
who had not received adjuvant chemotherapy  - median survival was not achieved. The 
difference in survival is statistically significant (р=0,008). 
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Fig. 6. Patients’ survival rate at early NSCLC stage with low р53 expression level depending on adjuvant 
chemotherapy  administration 
 
In the presence of early-stage NSCLC patients high p53 expression we have also 
detected a significant difference in survival rate for patients who had received adjuvant 
chemotherapy  and patients that had not received additional treatment (p = 0.002). In Fig. 8. it 
is shown that the median survival of patients with high p53 expression and conducted 
adjuvant chemotherapy  was not achieved. For patients with p53 overexpression and without 
additional treatment the median survival amounted to 31,0 ± 7,9 months. 
Thus, adjuvant chemotherapy  conducting for patients with p53 overexpression has a 
significant positive effect on survival of patients with stage I-II NSCLC. As opposed to this 
the conducting of additional postoperative chemotherapy for patients with low expression 
significantly worsensed their survival rate. 
Last molecular marker that has been analyzed is E-cadherin - cell adhesion marker. 
For patients with low E-cadherin expression level and that had not received adjuvant 
chemotherapy  the median survival was not achieved. While after the conducting of adjuvant 
chemotherapy  it equaled 20.0 months, this difference is not statistically significant (p = 
0.101). At the same time, survival rate of patients with high E-cadherin expression level was 
also not improved by adjuvant chemotherapy  (p = 0.452). Median survival was not achieved 
by both: patients after conducting of adjuvant chemotherapy  and patients that had not 
received additional postoperative treatment. 
Therefore, out of all analyzed markers the following ones are predicatively significant: 
Ki-67, CD31/CD34, Her-2/neu, p53, Pan-Cytokeratin.  
Ki-67, CD31/CD34, p53 low expression levels are adjuvant chemotherapy  negative 
impact marker on patients with early-stage NSCLC survival rate. On the contrary, at these 
markers high expression levels the adjuvant chemotherapy  appointment significantly 
improves the studied patients’ survival rate. Pan-Cytokeratin indicates the micrometastases 
presence the lymph nodes of root of the lung and for these types of patients the conducting of 
adjuvant chemotherapy  improves the survival rate. Her-2/neu is a marker of tumor 
chemoresistance, and for patients with high expression level of this marker, in particular, the 
conducting of adjuvant chemotherapy  is not reasonable, since this type of treatment does not 
improve survival rate under the specified marker characteristic. At the same time, low Her-
2/neu expression level is a marker of chemo sensitivity and the conducting of adjuvant 
chemotherapy  for such patients improves their survival rate. 
Patients’ median survival analysis with different molecular markers expression and 
conducting or absence of adjuvant chemotherapy  was carried out in order to confirm the 
obtained data (Table 1). 
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Table 1 І–ІІ stage NSCLC patients survival rate depending on the molecular markers expression level and 
prescribed treatment 
Marker Patients number Median survival  р 
Pan-Cytokeratin IHC (immune histochemical study) (-) 
Observations 104 NA* 0,884 Adjuvant chemotherapy  52 NA * 
Pan-Cytokeratin IHC (+) 
Observations 7 13,0±6,3 0,005 Adjuvant chemotherapy  17 NA * 
E-cadherin IHC (-) 
Observations 33 NA * 0,101 Adjuvant chemotherapy  29 20,0±4,0 
E-cadherin IHC (-) 
Observations 74 NA * 0,452 Adjuvant chemotherapy  33 NA * 
EGFR IHC (-) 
Observations 60 NA * 0,877 Adjuvant chemotherapy  42 NA * 
EGFR IHC (+) 
Observations 66 30,0±10,7 0,560 Adjuvant chemotherapy  31 25,0±6,3 
CD31/CD34 IHC (-) 
Observations 70 NA ** 0,005 Adjuvant chemotherapy  51 42,0±11,5 
CD31/CD34 IHC (+) 
Observations 73 30,0±8,9 0,003 Adjuvant chemotherapy  47 NA * 
р53 IHC (-) 
Observations 56 NA * 0,008 Adjuvant chemotherapy  38 26,0±5,3 
р53 IHC (+) 
Observations 84 31,0±7,9 0,002 Adjuvant chemotherapy  42 NA * 
Her-2-neu IHC (-) 
Observations 115 NA * 0,019 Adjuvant chemotherapy  58 NA * 
Her-2-neu IHC (+) 
Observations 30 21,0±2,5 0,88 Adjuvant chemotherapy  40 18,0±1,8 
Ki-67 IHC (-) 
Observations 63 NA * 
р<0,001 Adjuvant chemotherapy  34 25,0±3,7 
Ki-67 IHC (+) 
Observations 58 18,0±2,3 
р<0,001 Adjuvant chemotherapy  61 NA 
* Note: NA - not achieved 
 
As is evident from table data, the significant predictive connection of E-cadherin, 
EGFR expression level, high Her-2/neu expression and micrometastases absence was not 
detected. Further data meets the abovementioned and once again confirms the results. 
  
Conclusion 
1. Of all analyzed markers the following are predicatively important: Кі-67, 
CD31/CD34, Her-2/neu, p53 and Pan-Cytokeratin.  
2. Кі-67, CD31/CD34, р53 low expression level is adjuvant chemotherapy  negative 
impact marker for early stage NSCLC patients survival rate and vice versa at these markers 
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high expression levels the adjuvant chemotherapy  appointment significantly improves 
survival rates. 
3. Pan-Cytokeratin expression presence indicates micrometastases in lymph nodes of 
root of the lung, and for these patients the adjuvant chemotherapy  appointment improves 
survival rates.  
4. Her-2/neu is a marker of tumor chemoresistance. Thus, for patients with high 
expression level of this marker, in particular, the conducting of adjuvant chemotherapy  is not 
reasonable, since it does not improve survival rate. At the same time, the low Her-2/neu 
expression is a marker of chemo sensitivity and the appointment of adjuvant chemotherapy  
improves such atients’ survival rate significantly. 
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